This study aimed to evaluate the benefits and risks of patients with peripheral artery disease (PAD) treated with Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) by analyzing all the published studies on the clinical characteristics of patients with PAD.
Materials and Methods:
PubMed, Embase, and the Cochrane Library were searched for relevant studies. Efficacy, safety, and basic characteristics were analyzed.
Results:
Four studies were included in meta-analysis, including a total number of 155 patients with PAD. The pooled overall primary patency, freedom from target lesion revascularization (TLR), symptom resolution, and wound healing were 90%, 96%, 94%, and 86%, respectively. The pooled perioperative complication and all-cause mortality were 4% and 9%, respectively. Preoperative total occlusion was detected in 43 of 192 lesions (22%). The mean lesion length was 27.26 mm. In terms of comorbidities, the pooled percentage of hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, chronic kidney disease history, and smoking were 65%, 74%, 49%, 43%, 20%, and 57%, respectively.
Conclusion:
Among these studies, hypertension, hyperlipidemia, and diabetes mellitus were the most common comorbidities in patients with PAD. The Absorb everolimus-eluting BVS was safe and showed the favorable clinical outcomes in both patency and TLR, especially in infrapopliteal disease with heavy calcification. The conclusions of this meta-analysis still needed to be verified by more relevant studies with more careful design, more rigorous execution, and larger sample size.
NorgrenLHiattWRDormandyJA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–67.
2.
HirschATHaskalZJHertzerNR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239–1312.
3.
JaffMRWhiteCJHiattWR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): the TASC steering committee. Catheter Cardiovasc Interv. 2015;86(4):611–625.
4.
HuizingEKumSIpemaJ, et al. Mid-term outcomes of an everolimus-eluting bioresorbable vascular scaffold in patients with below-the-knee arterial disease: a pooled analysis of individual patient data. Vasc Med. 2021;26(2):195–199.
5.
JohnstonKW.Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology. 1992;183(3):767–771.
6.
SchillingerMSabetiSLoeweC, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–1888.
7.
KatsanosKKitrouPSpiliopoulosS, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23(6):851–863.
8.
ScheinertDKatsanosKZellerT, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60(22):2290–2295.
9.
RastanATepeGKrankenbergH, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32(18):2274–2281.
10.
JonerMFinnAVFarbA, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193–202.
11.
GrewePHDenekeTMachraouiA, et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol. 2000;35(1):157–163.
12.
FarbAWeberDKKolodgieFD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105(25):2974–2980.
13.
OtsukaFVorpahlMNakanoM, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211–223.
14.
TamaiHIgakiKKyoE, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102(4):399–404.
15.
SerruysPWOrmistonJAOnumaY, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897–910.
16.
SerruysPWOnumaYOrmistonJA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301–2312.
17.
NishioSKosugaKIgakiK, et al. Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012;125(19):2343–2353.
18.
VogtFSteinARettemeierG, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004;25(15):1330–1340.
19.
BanaresRAlbillosARinconD, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35(3):609–615.
20.
SlimKNiniEForestierD, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716.
21.
MoolaSMunnZSearsK, et al. Conducting systematic reviews of association (etiology): the Joanna Briggs Institute’s approach. Int J Evid Based Healthc. 2015;13(3):163–169.
22.
KumSIpemaJChun-YinDH, et al. Early and midterm experience with the Absorb everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening ischemia: one-year clinical and imaging outcomes from the DISAPEAR registry. J Endovasc Ther. 2020;27(4):616–622.
23.
LammerJBosiersMDelooseK, et al. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv. 2016;9(11):1178–1187.
24.
VarcoeRLThomasSDLennoxAF.Three-year results of the Absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2018;25(6):694–701.
25.
DiaAVenturiniJMKalathiyaRJ, et al. Two-year follow-up of bioresorbable vascular scaffolds in severe infra-popliteal arterial disease. Vascular. 2021;29:355–362.
26.
IyerSSDorrosGZaitounR, et al. Retrograde recanalization of an occluded posterior tibial artery by using a posterior tibial cutdown: two case reports. Cathet Cardiovasc Diagn. 1990;20(4):251–253.
27.
HirschATHaskalZJHertzerNR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654.
28.
RomitiMAlbersMBrochado-NetoFC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47(5):975–981.
29.
KrankenbergHSchluterMSteinkampHJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116(3):285–292.
30.
LairdJRKatzenBTScheinertD, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–276.
31.
LairdJRKatzenBTScheinertD, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9.
32.
Biondi-ZoccaiGGSangiorgiGLotrionteM, et al. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther. 2009;16(3):251–260.
33.
Rocha-SinghKJJaffMJoyeJ, et al. Major adverse limb events and wound healing following infrapopliteal artery stent implantation in patients with critical limb ischemia: the XCELL trial. Catheter Cardiovasc Interv. 2012;80(6):1042–1051.
34.
HeRYeYLiZ, et al. Restenosis prevention with drug eluting or covered stents in femoropopliteal arterial occlusive disease: evidence from a comprehensive network meta-analysis. Eur J Vasc Endovasc Surg. 2019;58(1):61–74.
35.
Muller-HulsbeckSKeirseKZellerT, et al. Twelve-month results from the MAJESTIC trial of the eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23(5):701–707.
36.
MustaphaJADiaz-SandovalLJSaabF.Infrapopliteal calcification patterns in critical limb ischemia: diagnostic, pathologic and therapeutic implications in the search for the endovascular holy grail. J Cardiovasc Surg (Torino). 2017;58(3):383–401.
37.
DruekeTB.Arterial intima and media calcification: distinct entities with different pathogenesis or all the same?Clin J Am Soc Nephrol. 2008;3(6):1583–1584.
38.
KatsanosKGeislerBPGarnerAM, et al. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open. 2016;6(5):e011245.
39.
PeregrinJHKoznarBKovacJ, et al. PTA of infrapopliteal arteries: long-term clinical follow-up and analysis of factors influencing clinical outcome. Cardiovasc Intervent Radiol. 2010;33(4):720–725.
40.
VarcoeRLSchoutenOThomasSD, et al. Experience with the Absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee: 12-month clinical and imaging outcomes. JACC Cardiovasc Interv. 2016;9(16):1721–1728.
41.
NeilN.Stent fracture in the superficial femoral and proximal popliteal arteries: literature summary and economic impacts. Perspect Vasc Surg Endovasc Ther. 2013;25(1–2):20–27.
42.
KarnabatidisDKatsanosKSpiliopoulosS, et al. Incidence, anatomical location, and clinical significance of compressions and fractures in infrapopliteal balloon-expandable metal stents. J Endovasc Ther. 2009;16(1):15–22.
43.
PatelNMecheryAKassimisG, et al. Novel indication for bioabsorbable scaffolds in metal allergy. EuroIntervention. 2014;10(4):495.
44.
OkamuraTSerruysPWRegarE.Three-dimensional visualization of intracoronary thrombus during stent implantation using the second generation, Fourier domain optical coherence tomography. Eur Heart J. 2010;31(5):625.
45.
VarcoeRLMentingTPThomasSD, et al. Long-term results of a prospective, single-arm evaluation of everolimus-eluting bioresorbable vascular scaffolds in infrapopliteal arteries. Catheter Cardiovasc Interv. 2021;97(1):142–149.
46.
SpuentrupERuebbenAMahnkenA, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation. 2005;111(8):1019–1026.
47.
EggebrechtHRodermannJHunoldP, et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation. 2005;112(18):e303–e304.
48.
StoneGWGaoRKimuraT, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277–1289.
49.
KimuraTKozumaKTanabeK, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332–3342.
50.
KereiakesDJEllisSGMetzgerC, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. J Am Coll Cardiol. 2017;70(23):2852–2862.
51.
WykrzykowskaJJKraakRPHofmaSH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376(24):2319–2328.
52.
AliZASerruysPWKimuraT, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390(10096):760–772.
53.
SotomiYOnumaYColletC, et al. Bioresorbable scaffold: the emerging reality and future directions. Circ Res. 2017;120(8):1341–1352.
54.
TenekeciogluEPoonEKColletC, et al. The nidus for possible thrombus formation: insight from the microenvironment of bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2016;9(20):2167–2168.
55.
BiaminoGSchmidtAScheinertD. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J Endovasc Ther. 2005;12(Suppl I):5.
56.
VermassenFBouckenoogheIMoreelsN, et al. Role of bioresorbable stents in the superficial femoral artery. J Cardiovasc Surg (Torino). 2013;54(2):225–234.
57.
LinniKUgurluogluAHitzlW, et al. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014;21(4):493–502.
58.
BosiersMPeetersPD’ArchambeauO, et al. AMS INSIGHT–absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32(3):424–435.
59.
DiaAVenturiniJMKalathiyaR, et al. Single arm retrospective study of bioresorbable vascular scaffolds to treat patients with severe infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2019;94(7):1028–1033.
60.
SpreenMIMartensJMHansenBE, et al. Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv. 2016;9(2):e002376.
61.
SpreenMIMartensJMKnippenbergB, et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc. 2017;6(4):e004877.
62.
VarcoeRLThomasSDRapozaRJ, et al. Lessons learned regarding handling and deployment of the Absorb bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2017;24(3):337–341.
63.
BarbatoEShlofmitzEMilkasA, et al. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses—from debulking to plaque modification, a 40-year-long journey. EuroIntervention. 2017;13(6):696–705.
64.
TanakaALatibAKawamotoH, et al. Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy. EuroIntervention. 2017;12(14):1730–1737.
65.
PuricelSCuculiFWeissnerM, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67(8):921–931.
66.
OnumaYSotomiYShiomiH, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12(9):1090–1101.
67.
WernerMSchmidtAScheinertS, et al. Evaluation of the biodegradable Igaki-Tamai scaffold after drug-eluting balloon treatment of de novo superficial femoral artery lesions: the GAIA-DEB Study. J Endovasc Ther. 2016;23(1):92–97.
